Bausch Health (BHC)
(Real Time Quote from BATS)
$8.24 USD
+0.06 (0.73%)
Updated Sep 20, 2024 02:08 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 81 - 100 ( 160 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Alaway Approval; VYZULTA Reach Widens; XIFAXAN Resolution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Allegro Ophthalmics Purchase Option Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Opthalmics-Focused Spinout Planned; 2Q20 Financials; Lowering PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Legacy Investigation Resolved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Pandemic Impact Abating; Universe Re-Rating; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department